{{medical}}

{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 407837023
| IUPAC_name = 參見[[#結構|結構]]一段
| image = Heparin.svg
| image2 = Heparin-3D-vdW.png

<!--Clinical data-->
| pronounce = ['hɛpərɪn]<br />{{respell|HEP|ə-rin}}
| Drugs.com = {{drugs.com|monograph|heparin-sodium}}
| pregnancy_category = C<ref>{{Cite web |url=http://www.fda.gov/safety/medwatch/safetyinformation/ucm219000.htm |title=Heparin Sodium injection<!-- Bot generated title --> |accessdate=2017-05-15 |archive-date=2017-01-25 |archive-url=https://web.archive.org/web/20170125194012/http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm219000.htm |dead-url=no }}</ref>
| legal_US = Rx-only
| legal_status = Rx-only
| routes_of_administration = [[靜脈注射|靜脈注射]]、[[皮下注射|皮下注射]]

<!--Pharmacokinetic data-->
| bioavailability = Erratic
| metabolism = 肝臟
| elimination_half-life = 1.5 小時
| excretion = Urine<ref>heparin. In: Lexi-Drugs Online [database on the Internet]. Hudson (OH): Lexi-Comp, Inc.; 2007 [cited 2/10/12]. Available from: http://online.lexi.com {{Wayback|url=http://online.lexi.com/ |date=20160106153052 }}. subscription required to view.</ref>

<!--Identifiers-->
| IUPHAR_ligand = 4214
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 9005-49-6
| ATC_prefix = B01
| ATC_suffix = AB01
| ATC_supplemental = {{ATC|C05|BA03}} {{ATC|S01|XA14}}
| PubChem = 22833565
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB01109
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 17216115
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = T2410KM04A
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 526514

<!--Chemical data-->
| C=12 | H=19 | N=1 | O=20 | S=3
| molecular_weight = 12000–15000 g/mol
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C26H41NO34S4/c1-4(28)27-7-9(30)8(29)6(2-52-63(43,44)45)53-24(7)56-15-10(31)11(32)25(58-19(15)21(36)37)55-13-5(3-62(40,41)42)14(60-64(46,47)48)26(59-22(13)38)57-16-12(33)17(61-65(49,50)51)23(39)54-18(16)20(34)35/h5-19,22-26,29-33,38-39H,2-3H2,1H3,(H,27,28)(H,34,35)(H,36,37)(H,40,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)/t5-,6+,7+,8+,9+,10+,11+,12-,13-,14+,15-,16-,17+,18+,19-,22-,23?,24+,25+,26-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ZFGMDIBRIDKWMY-PASTXAENSA-N
}}

<!-- Definition and medical uses -->
'''肝素'''（heparin）又稱'''普通肝素'''、'''未裂解肝素'''（unfractionated heparin，UFH），是一種天然且高度硫化的[[糖胺聚糖|糖胺聚糖]][[抗凝剂|抗凝血劑]]<ref name="AHFS2016">{{cite web|url=http://www.drugs.com/monograph/heparin-sodium.html|title=Heparin Sodium|accessdate=1 January 2016|publisher=The American Society of Health-System Pharmacists|archive-date=2016-01-27|archive-url=https://web.archive.org/web/20160127144903/http://www.drugs.com/monograph/heparin-sodium.html|dead-url=no}}</ref><ref name="UK2016">{{cite web|title=Heparin (Mucous ) Injection BP - Summary of Product Characteristics (SPC) - (eMC)|url=https://www.medicines.org.uk/emc/medicine/8308|website=www.medicines.org.uk|accessdate=15 December 2016|date=September 2016|archive-date=2016-12-20|archive-url=https://web.archive.org/web/20161220184640/https://www.medicines.org.uk/emc/medicine/8308|dead-url=no}}</ref>，也是所有生物分子中陰電密度最高的分子<ref name="cox">{{cite book |last = Cox | first = M. |author2=Nelson D. | title = Lehninger, Principles of Biochemistry | issue=4 | publisher = Freeman | year = 2004 | page=254 | isbn=0-7167-4339-6 }}</ref>平均分子量约15,000[[原子质量单位|道尔顿]]。肝素可用來治療及預防[[深静脉血栓|深靜脈血栓]]、[[肺栓塞|肺栓塞]]、[[動脈栓塞|動脈栓塞]]，也可用於治療[[心肌梗死|心肌梗塞]]以及[[不穩定型心絞痛|不穩定型心絞痛]]。通常以[[靜脈注射|靜脈注射]]方式給藥，也可以應用在[[试管|採血管]]以及[[血液透析|血液透析機]]。<ref name=UK2016/><ref>{{cite book|last1=McClatchey|first1=Kenneth D.|title=Clinical Laboratory Medicine|date=2002|publisher=Lippincott Williams & Wilkins|isbn=9780683307511|page=662|url=https://books.google.ca/books?id=3PJVLH1NmQAC&pg=PA662|language=en}}</ref>

<!-- Side effects and mechanism-->
肝素于1916年自狗的肝细胞分离而發現，故而得名<ref>{{cite book|last1=Li|first1=Jie Jack|last2=Corey|first2=E. J.|title=Drug Discovery: Practices, Processes, and Perspectives|date=2013|publisher=John Wiley & Sons|isbn=9781118354469|page=189|url=https://books.google.ca/books?id=mIyxO5cLEAcC&pg=PA189|language=en}}</ref>。使用肝素常見的副作用包括出血、注射部位疼痛以及[[血小板减少性紫癜|血小板減少症]]，嚴重可導致肝素誘發的血小板減少症（HIT）。雖然腎功能不佳者在使用肝素時需要特別留意，但對於[[妊娠|孕婦]]及[[母乳哺育|授乳的媽媽]]來說肝素是相當安全的。<ref>{{cite web|title=Heparin Pregnancy and Breastfeeding Warnings|url=http://www.drugs.com/pregnancy/heparin.html|website=drugs.com|accessdate=15 January 2016|archive-date=2016-01-27|archive-url=https://web.archive.org/web/20160127000923/http://www.drugs.com/pregnancy/heparin.html|dead-url=no}}</ref> 

低分子量肝素（low-molecular-weight heparin，LMWH）是平均分子量4500Da的肝素盐<ref>Conners MS 3rd, Money SR. The new heparins. Ochsner J. 2002;4(1):41-47.</ref>,由高分子肝素通过多种[[分提|分提]]或[[解聚|解聚]]方法得到。

<!-- Society and culture -->
肝素已列入[[世界卫生组织基本药物标准清单|世界衛生組織基本藥物標準清單]]中（能列入這個清單的，都是被認定為[[健康照護系統|健康照護系統]]中最安全與最有效的藥物）<ref name=WHO19th>{{cite web|title=WHO Model List of Essential Medicines (19th List)|url=http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|work=World Health Organization|accessdate=8 December 2016|date=April 2015|archive-date=2016-12-13|archive-url=https://web.archive.org/web/20161213052708/http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|dead-url=no}}</ref>。 在預防用途上，開發中國家的批發價大約是每個月9.63到 37.95 美金<ref name=ERC2014>{{cite web|title=Heparin|url=http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=HEP5000A&s_year=2014&year=2014&str=5000%20IU%2Fml&desc=Heparin&pack=new&frm=AMPOULE&rte=INJ&class_code2=10%2E2%2E&supplement=&class_name=%2810%2E2%2E%29Medicines%20affecting%20coagulation%3Cbr%3E|website=International Drug Price Indicator Guide|accessdate=8 December 2016}}{{dead link|date=2018年1月 |bot=InternetArchiveBot |fix-attempted=yes }}</ref>；在美國則是25到50美金<ref name=Ric2015>{{cite book|last1=Hamilton|first1=Richart|title=Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition|date=2015|publisher=Jones & Bartlett Learning|isbn=9781284057560|page=X}}</ref>。另外也有低分子量的肝素<ref>{{cite book|last1=Rietschel|first1=Robert L.|last2=Fowler|first2=Joseph F.|last3=Fisher|first3=Alexander A.|title=Fisher's Contact Dermatitis|date=2008|publisher=PMPH-USA|isbn=9781550093780|page=142|url=https://books.google.ca/books?id=dQBAzfyCeQ8C&pg=PA142|language=en}}</ref>。

==醫療用途==
[[File:Heparin_Sodium_sample.jpg|thumb]]
體內的[[嗜鹼性球|嗜鹼性球]]與[[肥大细胞|肥大細胞]]都可以合成肝素<ref>{{cite book |last = Guyton | first = A. C. |author2=Hall, J. E. | title = Textbook of Medical Physiology |url = https://archive.org/details/textbookmedicalp00guyt_565 | issue=11 | publisher = Elsevier Saunders | year = 2006 | page=[https://archive.org/details/textbookmedicalp00guyt_565/page/n499 464] | isbn=0-7216-0240-1}}</ref> 。雖然它只能預防血栓形成，不能像[[組織纖溶酶原激活劑|組織纖溶酶原激活劑]]（tPA 或PLAT）一樣把血栓溶解，但它可以防血栓擴大，接著體內的纖維蛋白溶解機制便可以將血栓溶解。適應症包括：
*[[急性冠状动脉综合症|急性冠狀動脈綜合症]]；
*[[心房顫動|心房顫動]]；
*[[深静脉血栓|深靜脈血栓]]與[[肺栓塞|肺栓塞]]；
*[[心脏外科|心臟外科手術]]使用[[體外循環機|體外循環機]]時；
*使用[[體外膜氧合|葉克膜]]時；
*使用血液過濾機；
*留置中央或外周靜脈導管。
雖然肝素與低分子量肝素（包括[[依诺肝素钠|依諾肝素]]、達肝素鈉與錫扎肝素鈉）對於預防[[深静脉血栓|深靜脈血栓]]與[[肺栓塞|肺栓塞]]都很有效<ref>{{cite journal|year=1998|title=Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery|journal=N Engl J Med|volume=339|issue=2|pages=80–5|doi=10.1056/NEJM199807093390204|pmid=9654538|author=Agnelli G|name-list-format=vanc|author2=Piovella F|author3=Buoncristiani P|display-authors=etal}}</ref><ref>{{cite journal|year=2002|title=Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer|url=http://content.nejm.org/cgi/content/abstract/346/13/975|journal=N Engl J Med|volume=346|issue=13|pages=975–980|doi=10.1056/NEJMoa012385|pmid=11919306|author=Bergqvist D|name-list-format=vanc|author2=Agnelli G|author3=Cohen AT|display-authors=etal|access-date=2017-05-15|archive-date=2010-01-05|archive-url=https://web.archive.org/web/20100105152646/http://content.nejm.org/cgi/content/abstract/346/13/975|dead-url=no}}</ref>，但目前的研究並未發現任何一種效果特別好<ref>{{cite journal|last2=Farrar|last3=McBirnie|last4=Tytherleigh-Strong|last5=Milne|last6=Gillespie|year=2002|title=Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures|journal=Cochrane Database Syst Rev|volume=|issue=4|pages=CD000305|doi=10.1002/14651858.CD000305|pmid=12519540|author=Handoll HHG, Farrar MJ, McBirnie J, Tytherleigh-Strong G, Milne AA, Gillespie WJ|editor1-last=Handoll|editor1-first=Helen HG}}</ref>。

==副作用==
最嚴重的副作用是肝素誘發的血小板減少症（HIT）。肝素誘發的血小板減少症是一種免疫反應，造成[[血小板|血小板]]成為[[免疫系统|免疫反應]]攻擊的目標，導致血小板分解、[[血小板减少性紫癜|血小板減少]]。通常停用後症狀會消失，而且可藉由使用合成肝素來避免其發生。除此之外，一開始使用肝素時也會出現輕微的血小板減少症，不過不需要停用。

另外兩個與出血無關的副作用是：有八成的患者在使用肝素後會出現[[血清轉胺酶|血清轉胺酶]]上升的現象，另外有百分之五到十的患者則會在使用肝素後出現[[高鉀血症|高鉀血症]]。使用肝素造成的血清轉胺酶上升與肝功能無關，在停用後就會恢復正常；高鉀血症則是因為肝素誘發了[[醛固酮|醛固酮]]分泌抑制所導致。長期使用肝素的患者有少數會出現[[脫髮|脫髮]]與[[骨質疏鬆症|骨質疏鬆]]。

過量使用肝素可以致命。2006年在[[印地安納波利斯|印地安納波里斯]]的一家醫院，有三名早產兒因為被錯誤注射成人劑量的肝素而死亡<ref>{{cite news | last = Kusmer | first = Ken | publisher = Fox News (Associated Press) | title = 3rd Ind. preemie infant dies of overdose | url = http://www.foxnews.com/story/0,2933,214729,00.html | date = 20 September 2006 | accessdate = 2007-01-08 | archive-url = https://web.archive.org/web/20071018064124/http://www.foxnews.com/story/0,2933,214729,00.html | archive-date = 2007-10-18 | dead-url = yes }}</ref>。

===禁忌症===
{{Refimprove section|date=2017年4月}}
對於有出血顧慮（尤其是血壓控制困難、肝病、中風）的患者，嚴重肝病、高血壓的患者不宜使用肝素<ref>{{Cite news|url=http://www.webmd.com/drugs/2/drug-3918/heparin-porcine-injection/details/list-contraindications|title=Contraindications for heparin (porcine) injection|newspaper=WebMD|accessdate=2017-04-25|language=en-US}}</ref>。

===解毒劑===
當使用過量的肝素時，可以在四小時內以每100單位1毫克的{{tsl|en|Protamine sulfate|硫酸魚精蛋白}}來消除肝素的作用<ref>''Internal medicine'', Jay H. Stein, page 635</ref><ref>{{cite web|title=Protamine Sulfate|url=https://www.drugs.com/monograph/protamine-sulfate.html|publisher=The American Society of Health-System Pharmacists|accessdate=8 December 2016|archive-date=2016-11-06|archive-url=https://web.archive.org/web/20161106063702/https://www.drugs.com/monograph/protamine-sulfate.html|dead-url=no}}</ref>。

==肝素的生理功能==
肝素在體內的功能未知。肥大細胞合成肝素後會儲存在分泌泡中，直到組織受傷時便會釋出。因此，它被認為在體內可能與防禦細菌與其他物質入侵有關<ref>{{cite journal  | title=Heparan sulfates and heparins: similar compounds performing the same functions in vertebrates and invertebrates? | journal= Braz. J. Med. Biol. Res. | year=1999 | volume=32 | issue=5 | pages=529–538 | pmid = 10412563  | doi=10.1590/S0100-879X1999000500005 |last1=Nader |first1= H.B.| last2=Chavante | first2=S.F. | last3=Dos-Santos | first3=E.A. | last4=Oliveira | first4=F.W. | last5=De-Paiva | first5=J.F. | last6=Jerônimo | first6=S.M.B. | last7=Medeiros | first7=G.F. | last8=De-Abreu | first8=L.R.D. | last9=Leite | first9=E.L.| displayauthors = 8 }}</ref>。肝素被懷疑在體內與抗凝血無關的另一個原因是，許多不具有與人類類似的凝血系統的無脊椎動物也會製造肝素。

===演化上的保留性===
除了可以由豬與牛的組織中萃取出製藥級的肝素之外，在以下這些生物中也都曾萃取出肝素：
{{colbegin|火雞|22em}}
# {{tsl|en|Domestic turkey||火雞}}<ref>{{cite journal | author= Warda M  | title = Turkey intestine as a commercial source of heparin? Comparative structural studies of intestinal avian and mammalian glycosaminoglycans | journal= Comp. Biochem. Physiol. B Biochem. Mol. Biol. | year=2003 | volume=134 | issue=1 | pages=189–197 | pmid = 12524047  | doi = 10.1016/S1096-4959(02)00250-6|name-list-format=vanc | author2 =  Mao W. |display-authors=etal}}</ref>
# [[鯨|鯨]]<ref>{{cite journal | author= Ototani N, Kikuchi M, Yosizawa Z. | title = Comparative studies on the structures of highly active and relatively inactive forms of whale heparin | journal= J Biochem (Tokyo) | year=1981 | volume=90 | issue=1 | pages=241–246 | pmid = 7287679| last2 = Kikuchi | last3 = Yosizawa }}</ref>
# [[單峰駱駝|單峰駱駝]]<ref>{{cite journal | author= Warda M | title = Isolation and characterization of raw heparin from dromedary intestine: evaluation of a new source of pharmaceutical heparin | journal= Comp. Biochem. Physiol. C Toxicol. Pharmacol. | year=2003 | volume=136 | issue=4 | pages=357–365 | pmid = 15012907 | doi= 10.1016/j.cca.2003.10.009|name-list-format=vanc | author2 =  Gouda EM. |display-authors=etal}}</ref>
# [[小鼠属|鼠]]<ref>{{cite journal | author= Bland CE | title = Mouse heparin proteoglycan. Synthesis by mast cell-fibroblast monolayers during lymphocyte-dependent mast cell proliferation | journal= J. Biol. Chem. | year=1982 | volume=257 | issue=15 | pages=8661–8666 | pmid = 6807978|name-list-format=vanc | author2 =  Ginsburg H. |display-authors=etal}}</ref>
# [[人|人]]<ref>{{cite journal | author= Linhardt RJ | title = Isolation and characterization of human heparin | journal= Biochemistry | year=1992 | volume=31 | issue=49 | pages=12441–12445 | pmid = 1463730 | doi= 10.1021/bi00164a020|name-list-format=vanc | author2 =  Ampofo SA. |display-authors=etal}}</ref>
# [[美洲螯龍蝦|龍蝦]]<ref>{{cite journal | author= Hovingh P, Linker A. | title = An unusual heparan sulfate isolated from lobsters (Homarus americanus) | journal= J. Biol. Chem. | year=1982 | volume=257 | issue=16 | pages=9840–9844 | pmid = 6213614| last2 = Linker }}</ref>
# {{tsl|en|Anodonta californiensis||淡菜}}<ref>{{cite journal | author=Hovingh P, Linker A. | title=Glycosaminoglycans in ''Anodonta californiensis'', a freshwater mussel | journal=Biol. Bull | year=1993 | volume=185 | issue=2 | pages=263–276 | url=http://www.biolbull.org/cgi/content/abstract/185/2/263 | doi=10.2307/1542006 | jstor=1542006 | last2=Linker | access-date=2017-05-15 | archive-url=https://web.archive.org/web/20110616194920/http://www.biolbull.org/cgi/content/abstract/185/2/263 | archive-date=2011-06-16 | dead-url=yes }}</ref>
# [[蛤蜊|蛤]]<ref>{{cite journal | author= Pejler G | title =Structure and antithrombin-binding properties of heparin isolated from the clams Anomalocardia brasiliana and Tivela mactroides | journal= J. Biol. Chem. | year=1987 | volume=262 | issue=24 | pages=11413–11421 | pmid = 3624220|name-list-format=vanc | author2 = Danielsson A. |display-authors=etal}}</ref>
# [[Penaeus_brasiliensis|蝦]]<ref>{{cite journal | author=Dietrich CP | title = Structural features and anticoagulant activities of a novel natural low-molecular-weight heparin from the shrimp Penaeus brasiliensis | journal= Biochim. Biophys. Acta | year=1999 | volume=1428 | issue=2–3 | pages=273–283 | pmid = 10434045 | doi=10.1016/S0304-4165(99)00087-2|name-list-format=vanc | author2 =  Paiva JF. |display-authors=etal}}</ref>
# {{tsl|en|Mangrove crab||紅樹林蟹}}<ref name=medeiros>{{cite journal | author=Medeiros GF | title = Distribution of sulfated glycosaminoglycans in the animal kingdom: widespread occurrence of heparin-like compounds in invertebrates | journal= Biochim. Biophys. Acta | year=2000 | volume=1475 | issue=3 | pages=287–294 | pmid = 10913828 | doi=10.1016/S0304-4165(00)00079-9|name-list-format=vanc | author2 =  Mendes | author3 =  A. |display-authors=etal}}</ref>
# [[沙錢|沙錢]]<ref name=medeiros/>
#[[大西洋鮭魚|大西洋鮭魚]]<ref>Flengsrud, R., Lie Larsen, M., Ødegaard, OR. (2010). "Purification, characterization and in vivo studies of salmon heparin".  ''Thrombosis Research'', 126: e409–e417 . doi:10.1016/j.thromres.2010.07.004</ref><ref>{{cite journal | author = Flengsrud R | year = 2016 | title = Disaccharide analysis of chondroitin and heparin from farmed Atlantic salmon | url = | journal = Glycoconjugate Journal | volume = 33 | issue = 2| pages = 121–123 | doi = 10.1007/s10719-016-9652-8 }}</ref>
#[[斑馬魚|斑馬魚]] <ref>{{cite journal | author = Zhang F., Zhang Z., Thistle R., McKeen L. ''et al.'' | year = 2009 | title = Structural characterization of glycosaminoglycans from zebrafish in different ages | url = | journal = Glycoconj. Journal | volume = 26 | issue = 2| pages = 211–218 | doi = 10.1007/s10719-008-9177-x }}</ref>
{{colend}}
由於項目6-11的生物並不具有與人類類似的凝血系統，進一步支持了肝素可能與抗凝血無關的說法。

== 藥理學 ==
[[自然|自然界]]的肝素是一群分子量多變的[[聚合物|聚合物]]。普通肝素指的是沒有將低分子量肝素分離出來的肝素，而低分子量肝素則是將低分子量部分分離出來，以使其療效變得較為可預測。不論是普通肝素或低分子量肝素都可以在臨床下使用，有些症狀使用其中一種效果會比較好<ref name="pmid_16030035">{{Citation |last=Hetzel |first=GR |year=2005 |title=The heparins: all a nephrologist should know |journal=Nephrol Dial Transplant |volume=20 |issue=10 |pages=2036–2042 |pmid=16030035 |doi=10.1093/ndt/gfi004 |postscript=.|display-authors=etal}}</ref>。

===作用機制<!--LMWH links here-->===
肝素經由它的硫化五糖序列與酵素抑制劑{{tsl|en|antithrombin|抗凝血酶}}III結合，使其構形改變而活化<ref>{{cite journal | author = Chuang YJ | title = Heparin enhances the specificity of antithrombin for thrombin and factor Xa independent of the reactive center loop sequence. Evidence for an exosite determinant of factor Xa specificity in heparin-activated antithrombin | journal= J. Biol. Chem. | year= 2001 | volume= 276 | issue= 18 | pages= 14961–14971 | pmid = 11278930 | doi = 10.1074/jbc.M011550200|name-list-format=vanc | author2 =  Swanson R. |display-authors=etal}}</ref>。 活化的抗凝血酶III接著抑制[[凝血酶|凝血酶]]與{{tsl|en|factor Xa|凝血因子Xa}}以及其他蛋白酶，抑制的效果可因為肝素的加入而上升一千倍<ref>{{cite journal | author = Bjork I, Lindahl U. | title = Mechanism of the anticoagulant action of heparin | url = http://www.springerlink.com/content/g67115564280w013/ | journal = Mol. Cell. Biochem. | year = 1982 | volume = 48 | pages = 161–182 | doi = 10.1007/BF00421226 | pmid = 6757715 | issue = 3 | last2 = Lindahl | access-date = 2017-05-15 | archive-date = 2020-04-11 | archive-url = https://web.archive.org/web/20200411143244/http://www.springerlink.com/content/g67115564280w013/ | dead-url = yes }}</ref>。硫化五糖序列如下：

GlcNAc/NS(6S)-GlcA-GlcNS(3S,6S)-IdoA(2S)-GlcNS(6S)

抗凝血酶III與肝素結合後導致的構形改變，造成它可抑制凝血因子Xa。至於凝血酶與抗凝血酶III之間的作用，除了酵素以外，還需要同時與肝素結合形成{{tsl|en|ternary complex|三元複合體}}才能達到抑制的效果；這部分肝素的高陰電性擔任了重要的角色<ref name="cox" />。因此，至少要具有十八個糖的肝素才能與凝血酶及抗凝血酶III產生有效的作用；但是與凝血因子Xa的作用只需要硫化五糖序列就可以了<ref name="HerbertPetitou1999">{{cite journal|last1=Herbert|first1=Jean-Marc|last2=Petitou|first2=Maurice|last3=Hérault|first3=Jean-Pascal|last4=Bernat|first4=André|last5=Driguez|first5=Pierre-Alexandre|last6=Duchaussoy|first6=Philippe|last7=Lormeau|first7=Jean-Claude| title= Synthesis of Thrombin inhibiting Heparin mimetics without side effects|journal=Nature|volume=398|issue=6726|year=1999|pages=417–422|issn=0028-0836|doi=10.1038/18877| displayauthors= 4| pmid= 10201371}}</ref>。 這就是為何會開發出低分子量肝素與{{tsl|en|fondaparinux|磺達肝素}}（其化學結構幾乎與肝素/硫酸肝素的硫化五糖序列相同）之因：低分子量肝素與磺達肝素可以只抑制凝血因子Xa而不抑制凝血酶，如此一來不僅可以微調凝血系統，達到更好的治療效果；還能降低骨質疏鬆與肝素誘發的血小板減少症發生的風險。因為這兩種藥物只影響凝血因子Xa，在使用這兩種藥物時便不需進行活化性{{tsl|en|APTT|部分凝血酶時間}}測試（APTT）。

對於肝素誘發的血小板減少症患者，可以使用不含有肝素或肝素片段的{{tsl|en|Danaparoid||Danaparoid}}：它是硫酸肝素、{{tsl|en|dermatan sulfate|硫酸皮膚素}}與[[硫酸軟骨素|硫酸軟骨素]]的混合物，因為不含有肝素或肝素片段，所以只有不到10%的患者出現抗體交叉反應<ref>Shalansky, Karen. [http://www.vhpharmsci.com/Newsletters/1990s-NEWS/article6.htm DANAPAROID (Orgaran) for Heparin-Induced Thrombocytopenia.] {{Wayback|url=http://www.vhpharmsci.com/Newsletters/1990s-NEWS/article6.htm |date=20170622124338 }} Vancouver Hospital & Health Sciences Centre, February 1998 Drug & Therapeutics Newsletter. Retrieved on 8 January 2007.</ref>。 

肝素的效果通常以活化性部分凝血激素時間測試來監測。活化性部分凝血激素時間測試是試驗血漿凝固的時間，與[[凝血酶原時間|凝血酶原時間]]測試不同。

===使用方式===
因為肝素是個高陰電性的大分子，一般以靜脈注射或皮下注射方式給藥；不建議以肌肉注射方式給藥，因為會造成[[血腫|血腫]]。由於普通肝素在生物體內的半衰期約為一到二小時，因此若能以點滴的方式給予效果會較佳<ref name="pmid12358583">{{cite journal | author=Eikelboom JW, Hankey GJ | title=Low molecular weight heparins and heparinoids | journal=The Medical Journal of Australia | volume=177 | issue=7 | year=2002 | pages=379–383 | url=http://www.mja.com.au/public/issues/177_07_071002/eik10205_fm.html | id= | pmid=12358583 | last2=Hankey | access-date=2017-05-15 | archive-date=2011-09-09 | archive-url=https://web.archive.org/web/20110909061753/http://www.mja.com.au/public/issues/177_07_071002/eik10205_fm.html | dead-url=no }}</ref>。低分子量肝素的半衰期較長，約為四到五小時；因此可以以每天一劑的方式給予<ref>{{cite journal | author=Weitz JI | title=New anticoagulants for treatment of venous thromboembolism | journal=Circulation | volume=110 | issue=9 Suppl 1 | year=2004 | pages=I19–26 | url=http://circ.ahajournals.org/content/110/9_suppl_1/I-19.long | id= | pmid=15339877 | doi=10.1161/01.CIR.0000140901.04538.ae | access-date=2017-05-15 | archive-date=2018-06-29 | archive-url=https://web.archive.org/web/20180629212842/http://circ.ahajournals.org/content/110/9_suppl_1/I-19.long | dead-url=no }}</ref>。在長期抗凝血劑的治療上，肝素一般只使用到口服抗凝血劑（如：[[華法林|華法林]]）開始發揮作用即停止給藥。

{{tsl|en|American College of Chest Physicians|美國胸內科醫師學會}}已針對肝素劑量出版臨床指引<ref>{{cite journal|last1=Hirsh|first1=Jack|last2=Raschke|first2=Robert|title=Heparin and Low-Molecular-Weight Heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy|journal=Chest|date=September 2004|volume=126|issue=3|pages=188S–203S|doi=10.1378/chest.126.3_suppl.188S|pmid=15383472|accessdate=24 January 2017}}</ref>。 

===自然降解或清除===
普通肝素的半衰期約為一到二小時，<ref name="pmid12358583" />低分子量肝素的半衰期約為四到五小時。[[巨噬细胞|巨噬細胞]]會吞噬並分解與它結合的肝素，[[內皮細胞|內皮細胞]]則會藉著與肝素的結合使其無法與抗凝血酶III發生連結。高劑量的肝素會使內皮細胞與其結合的位置出現飽和的現象；雖然腎臟也會清除肝素，但速度很慢<ref>{{cite journal | author=Weitz DS, Weitz JI | title=Update on heparin: what do we need to know? | journal=Journal of Thrombosis and Thrombolysis  | volume=29 | issue=2 | year=2010 | pages=199–207  | id= | pmid=19882363 | doi=10.1007/s11239-009-0411-6| last2=Weitz }}</ref>，這也就是為何低劑量的肝素半衰期比高劑量短的原因。

== 化學 ==

=== 肝素的結構 ===
[[File:Heparin_ball-and-stick.png|thumb]]。]]
雖然大部分製藥級的肝素的[[分子量|分子量]]介於 12 到 15 [[原子质量单位|kDa]]之間，天然的肝素的分子量可以從 3 到 30 kDa<ref name=Francis>{{cite book | vauthors = Francis CW, Kaplan KL | chapter = Chapter 21. Principles of Antithrombotic Therapy | veditors = Lichtman MA, Beutler E, Kipps TJ | title = Williams Hematology | edition = 7th | year = 2006 | url = http://www.accessmedicine.com/content.aspx?aID=2138678 | isbn = 978-0-07-143591-8 | display-editors = etal | deadurl = yes | archiveurl = https://web.archive.org/web/20110707080715/http://www.accessmedicine.com/content.aspx?aID=2138678 | archivedate = 2011-07-07 }}</ref>。肝素以及硫酸肝素都屬於[[碳水化合物|碳水化合物]]家族中的[[糖胺聚糖|糖胺聚醣]]，由重複的硫化雙糖單位組成<ref>{{cite journal | last = Bentolila | first = A. | title = Synthesis and heparin-like biological activity of amino acid-based polymers | publisher = Wiley InterScience | url = http://onlinelibrary.wiley.com/doi/10.1002/1099-1581(200008/12)11:8/12<377::AID-PAT985>3.0.CO;2-D/abstract | subscription = yes | accessdate = 2008-03-10 | display-authors = etal | doi = 10.1002/1099-1581(200008/12)11:8/12<377::AID-PAT985>3.0.CO;2-D | volume = 11 | journal = Polymers for Advanced Technologies | pages = 377–387 | author =  | archive-url = https://web.archive.org/web/20101208234727/http://onlinelibrary.wiley.com/doi/10.1002/1099-1581%28200008/12%2911%3A8/12%3C377%3A%3AAID-PAT985%3E3.0.CO%3B2-D/abstract | archive-date = 2010-12-08 | dead-url = yes }}</ref>。在肝素中較常出現的雙糖單元包括了以下這六種類型，最常見（牛肺中約佔85%，豬腸黏膜則有75%）的是由 2-O-硫化{{le|艾杜醣醛酸|Iduronic acid}}與 6-O-硫化, N-硫化[[葡萄糖胺|葡萄糖胺]]（IdoA(2S)-GlcNS(6S)）所組成<ref name="GattiCasu1979">{{cite journal|last1=Gatti|first1=G.|last2=Casu|first2=B.|last3=Hamer|first3=G. K.|last4=Perlin|first4=A. S.|title=Studies on the Conformation of Heparin by1H and13C NMR Spectroscopy|journal=Macromolecules|volume=12|issue=5|year=1979|pages=1001–1007|issn=0024-9297|doi=10.1021/ma60071a044}}</ref>。

極少出現的雙糖單元是由含有 3-O-硫化葡萄糖胺（GlcNS(3S,6S)） 或含有胺基的葡萄糖（GlcNH<sub>3</sub><sup>+</sup>）所組成的雙糖單元。

在生理狀況下，肝素的[[酯|酯基]]與[[酰基|酰胺基]]會去質子化並吸引帶正電的離子來形成鹽類，製藥級的肝素通常也是以鹽類的方式給予。

一[[威廉·亨利·豪威爾|豪威爾]]單位的肝素大約等於 0.002 毫克的肝素。肝素的單位是以可以在攝氏零度下維持 1 毫升的貓血不凝固 24小時來制訂的<ref>{{cite web|url=http://cancerweb.ncl.ac.uk/cgi-bin/omd?Howell+unit|archive-url=https://archive.is/20070813174048/http://cancerweb.ncl.ac.uk/cgi-bin/omd?Howell+unit|dead-url=yes|archive-date=2007-08-13|title=Online Medical Dictionary|accessdate=2008-07-11|publisher=Centre for Cancer Education|year=2000}}</ref>。

<gallery>
File:GlcA-GlcNAc.png|<center>'''GlcA-GlcNAc'''</center>
File:GlcA-GlcNS.png|<center>'''GlcA-GlcNS'''</center>
File:IdoA-GlcNS.png|<center>'''IdoA-GlcNS'''</center>
File:IdoA(2S)-GlcNS.png|<center>'''IdoA(2S)-GlcNS'''</center>
File:IdoA-GlcNS(6S).png|<center>'''IdoA-GlcNS(6S)'''</center>
File:IdoA(2S)-GlcNS(6S).png|<center>'''IdoA(2S)-GlcNS(6S)'''</center>
</gallery>

====縮寫====

*'''GlcA''' = β-{{small|D}}-[[葡萄糖醛酸|葡萄糖醛酸]]
*'''IdoA''' = α-{{small|L}}-[[艾杜糖醛酸|艾杜糖醛酸]]
*'''IdoA(2S)''' = 2-''O''-硫-α-{{small|L}}-艾杜糖醛酸
*'''GlcNAc''' = 2-去氧-2-乙酰氨基-α-{{small|D}}-吡喃葡萄糖基
*'''GlcNS''' = 2-去氧-2-乙酰氨基-α-{{small|D}}-吡喃葡萄糖基
*'''GlcNS(6S)''' = 2-去氧-2-乙酰氨基-α-{{small|D}}-吡喃葡萄糖基-6-''O''-硫酸鹽

====立體結構====

因為艾杜糖醛酸在寡糖內部可以以兩種不同的構形存在，使肝素具有複雜的立體結構。除此之外，鄰近的葡萄糖胺的硫化程度也會對構形產生影響<ref>{{cite journal |vauthors=Ferro D, Provasoli A | title=Conformer populations of L-iduronic acid residues in glycosaminoglycan sequences | journal = Carbohydr. Res. | year=1990 | volume=195 | pages=157–167 | pmid = 2331699  | doi=10.1016/0008-6215(90)84164-P | issue=2|display-authors=etal}}</ref>。 1993年，以核磁共振光譜儀與分子建模這兩種技術，已將由六個2-去氧-2-乙酰氨基-α-{{small|D}}-吡喃葡萄糖基-6-''O''-硫酸鹽-2-''O''-硫-α-{{small|L}}-艾杜糖醛酸組成的肝素立體結構解出<ref>{{cite journal | author = Mulloy B, Forster MJ, Jones C, Davies DB. | title = N.M.R. and molecular-modelling studies of the solution conformation of heparin | journal = Biochem. J. | date=1 January 1993| volume=293 | pages=849–858 | pmid = 8352752 | issue = Pt 3 | pmc = 1134446 | last2 = Forster | last3 = Jones | last4 = Davies | doi=10.1042/bj2930849}}</ref> ，並得到兩種模型。其一是所有的2-''O''-硫-α-{{small|L}}-艾杜糖醛酸都在 <sup>2</sup>S<sub>0</sub> 構形 （如下圖 '''A''' 與 '''B'''）, 第二個則是都在 <sup>1</sup>C<sub>4</sub> 構形 （如下圖 '''C''' 與 '''D'''）。不過，目前沒有任何證據支持單一肝素分子內所有的2-''O''-硫-α-{{small|L}}-艾杜糖醛酸都只會有一種構形。這些模型對應到蛋白質資料庫代碼 1HPN<ref>{{cite web |url=http://www.rcsb.org/pdb/files/1hpn.pdb |author=B. Mulloy, M.J. Forster |title=N.M.R. and molecular-modeling studies of the solution conformation of heparin |accessdate=October 2016 |archive-date=2008-10-11 |archive-url=https://web.archive.org/web/20081011120801/http://www.rcsb.org/pdb/files/1hpn.pdb |dead-url=yes }}</ref> 。

{{wide image|Heparin-3D-structures.png|600px|兩個不同結構的肝素}}

上圖：
*'''A''' = 1HPN （所有的2-''O''-硫-α-{{small|L}}-艾杜糖醛酸都在 <sup>2</sup>S<sub>0</sub> 構形 ）[https://web.archive.org/web/20110928090536/http://wiki.jmol.org/index.php/User:K.murphy Jmol viewer]
*'''B''' = A 的[[凡得瓦半徑|凡得瓦半徑]]空間填充模型
*'''C''' = 1HPN （所有的2-''O''-硫-α-{{small|L}}-艾杜糖醛酸都在 <sup>1</sup>C<sub>4</sub> 構形 ）  [https://web.archive.org/web/20110928090536/http://wiki.jmol.org/index.php/User:K.murphy Jmol viewer]
*'''D''' = C 的[[凡得瓦半徑|凡得瓦半徑]]空間填充模型

在這些模型中，肝素呈現了螺旋狀的構形；不論在螺旋軸任一側，其旋轉的角度都會讓硫酸根以 17 [[埃|埃]]（1.7 [[奈米|奈米]]）的間隔錯開。

===解聚技術===
以化學及/或酵素將肝素解聚的技術，對於肝素或硫酸肝素的結構與功能的研究有重大的貢獻。

====酵素解聚====
分解肝素與硫酸肝素的酵素通常來自於土壤中的[[解肝磷脂土地桿菌|解肝磷脂土地桿菌]]<ref>{{cite journal | author= Shaya D | title = Crystal structure of heparinase II from Pedobacter heparinus and its complex with a disaccharide product | journal= J. Biol. Chem. | year=2006 | volume=281 | issue=22 | pages=15525–15535 | pmid = 16565082 | doi = 10.1074/jbc.M512055200|name-list-format=vanc | author2 =  Tocilj A. |display-authors=etal}}</ref>。解肝磷脂土地桿菌以肝素或硫酸肝素作為它的唯一碳源，為了分解肝素與硫酸肝素，解肝磷脂土地桿菌產生[[裂合酶|裂解酶]]，葡糖苷酸酶，磺基酯酶和磺酰胺酶<ref>{{cite journal | author= Galliher PM | title = Heparinase production by Flavobacterium heparinum | url= https://archive.org/details/sim_applied-and-environmental-microbiology_1981-02_41_2/page/n35 | journal= Appl. Environ. Microbiol. | year=1981 | volume=41 | issue=2 | pages=360–365 | pmid = 7235692 | pmc= 243699|name-list-format=vanc | author2 =  Cooney CL. |display-authors=etal}}</ref> ，最常使用的是裂解酶。解肝磷脂土地桿菌共產生三種裂解酶：肝素酶 I （{{EC number|4.2.2.7}}）、肝素酶 II （沒有[[EC編號|EC編號]]）、肝素酶 III （{{EC number|4.2.2.8}}），這三個酵素的專一性詳見下表： <ref>{{cite journal | author= Linhardt RJ | title = Examination of the substrate specificity of heparin and heparan sulfate lyases | journal= Biochemistry | year=1990 | volume=29 | issue=10 | pages=2611–2617 | pmid = 2334685 | doi = 10.1021/bi00462a026|name-list-format=vanc | author2 =  Turnbull JE. |display-authors=etal}}</ref><ref>{{cite journal |author1=Desai UR |author2=Wang HM. |author3=Linhardt RJ. | title = Specificity studies on the heparin lyases from Flavobacterium heparinum | journal= Biochemistry | year=1993 | volume=32 | issue=32 | pages=8140–8145 | pmid = 8347612 | doi = 10.1021/bi00083a012}}</ref>

{| class="wikitable" style="text-align:left"
|- valign="top"
| |'''肝素酶'''||'''對受質的專一性（辨認的醣類序列）'''
|- valign="top"
||  肝素酶 I || GlcNS(±6S)-IdoA(2S)
|-
|| 肝素酶 II || GlcNS/Ac(±6S)-IdoA(±2S)<br /> GlcNS/Ac(±6S)-GlcA
|-
|| 肝素酶 III || GlcNS/Ac(±6S)-GlcA/IdoA (with a preference for GlcA)
|}
[[File:UA(2S)-GlcNS(6S).svg|thumb]]
肝素酶以[[β-氫消除反應|β-氫消除反應]]機制來分解肝素與硫酸肝素，這個機制會在糖醛酸的四號碳與五號碳之間產生一個不穩定的雙鍵<ref>{{cite journal | author= Linker A, Hovingh P.| title = Isolation and characterization of oligosaccharides obtained from heparin by the action of heparinase | journal= Biochemistry | year=1972 | volume=11 | issue=4 | pages=563–568 | pmid = 5062409| doi = 10.1021/bi00754a013| last2 = Hovingh }}</ref><ref>{{cite journal | author= Linhardt RJ | title = Mapping and quantification of the major oligosaccharide components of heparin | journal= Biochem. J. | year=1988 | volume=254 | issue=3 | pages=781–787 | pmid = 3196292 | pmc= 1135151|name-list-format=vanc | author2 =  Rice KG. |display-authors=etal}}</ref>。由於這個具有不穩定雙鍵的糖醛酸（稱為 ΔUA 或 UA）會吸收232奈米紫外光，因此在實驗室常用232奈米吸收的變化來監控肝素酶的反應。

====化學解聚====
在pH1.5或4之下，[[亞硝酸|亞硝酸]]可用於肝素與硫酸肝素的化學解聚。 在這兩種條件下，亞硝酸會使肝素糖鏈發生脫氨裂解<ref>{{cite journal | author= Shively JE, Conrad HE. | title = Formation of anhydrosugars in the chemical depolymerization of heparin | journal= Biochemistry | year=1976 | volume=15 | issue=18 | pages=3932–3942 | pmid = 9127 | doi = 10.1021/bi00663a005| last2 = Conrad }}</ref>。脫氨裂解發生在GlcNS-GlcA以及GlcNS-IdoA之間，氧原子是否硫化並不受影響，不過在較高的pH值下進行反應時，速率會較慢。 [[File:reduction_fig.png|thumb]] 在較低的pH條件下，脫氨裂解會釋放出無機硫酸根與由2-去氧-2-乙酰氨基-α-{{small|D}}-吡喃葡萄糖基轉化而成的無水甘露糖。由於組成[[硫化軟骨素|硫化軟骨素]]與[[硫化皮膚素|硫化皮膚素]]的多糖其氮原子並未硫化，而亞硝酸無法在較低的pH條件下裂解氮未硫化的多糖，使此法可用來分辨肝素/硫酸肝素與硫化軟骨素/硫化皮膚素。

===肝素在體液中的偵測方式===
臨床上主要是以[[活化性部分凝血激素時間測試|活化性部分凝血激素時間測試]]或抗凝血因子Xa活性測試等間接的方式來測試肝素是否發揮效用，而不是直接偵測肝素的存在。進行這些測試需要新鮮、未溶血以檸檬酸、氟化物或草酸鹽作為抗凝血劑處理過的血漿<ref>{{cite journal |vauthors=Hansen R, Koster A, Kukucka M, Mertzlufft F, Kuppe H |title=A quick anti-Xa-activity-based whole blood coagulation assay for monitoring unfractionated heparin during cardiopulmonary bypass: a pilot investigation |journal=Anesth. Analg. |volume=91 |issue=3 |pages=533–8 |year=2000 |pmid=10960371 |doi= 10.1213/00000539-200009000-00006|url=https://archive.org/details/sim_anesthesia-and-analgesia_2000-09_91_3/page/533}}</ref><ref>R. Baselt, ''Disposition of Toxic Drugs and Chemicals in Man'', 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 728-729.</ref>。

==肝素的歷史==
肝素是在1916年[[威廉·亨利·豪威爾|威廉·亨利·豪威爾]]與他的學生[[傑·麥克萊恩|傑·麥克萊恩]]在[[約翰·霍普金斯大學|約翰·霍普金斯大學]]從狗的肝細胞中分離出來的，所以被命名為肝素（希臘文''hepar''是肝的意思，加上字尾-in）。雖然1916年就發現了肝素，不過一直到1935年才開始進行臨床測試<ref>{{cite web|title=Heparin used as an anticoagulant|publisher=AnimalResearch.info|url=http://animalresearch.info/en/medical-advances/145/heparin-used-as-an-anticoagulant/|accessdate=2017-05-15|archive-date=2013-10-23|archive-url=https://web.archive.org/web/20131023120406/http://animalresearch.info/en/medical-advances/145/heparin-used-as-an-anticoagulant/|dead-url=no}}</ref>。

麥克萊恩當時正在狗的肝臟組織中找尋可以促進凝血的物質，卻發現了脂溶性磷脂抗凝血分子<ref>{{cite journal|last=MCLEAN|first=J.|title=The Discovery of Heparin|url=https://archive.org/details/sim_circulation_1959-01_19_1/page/75|journal=Circulation|date=1 January 1959|volume=19|issue=1|pages=75–78|doi=10.1161/01.CIR.19.1.75|pmid=13619023}}</ref>；豪威爾在1918年把它命名為肝素。到了1920年代初，豪威爾又分離出了一個水溶性的抗凝血分子，雖然這個分子與麥克萊恩分離出來的分子特性不同，但豪威爾還是給它同樣的名字<ref>{{cite journal | author = Howell, W H. | title = Heparin, an anticoagulant. | journal = Am J Physiol. | year=1922 | volume=63 | pages=434–435 }}</ref><ref>{{cite journal | author = Mueller RL, Scheidt, S | title = History of drugs for thrombotic disease. Discovery, development, and directions for the future. | url = https://archive.org/details/sim_circulation_1994-01_89_1/page/432 | journal = Circulation | year=1994 | volume= 89| pages=432–449 | PMID=8281678 | doi=10.1161/01.cir.89.1.432}}</ref>。

到了1930年代，許多科學家都在研究肝素；其中[[卡羅琳學院|卡羅琳學院]]的艾瑞克·傑普斯在1935年解出了肝素的結構<ref>{{cite journal |author=Jorpes E |title=The chemistry of heparin |journal=The Biochemical Journal |volume=29 |issue=8 |pages=1817–30 |date=August 1935 |pmid=16745848 |pmc=1266692}}</ref>，使瑞典的Vitrum AB藥廠得以在1936年生產第一個靜脈注射的肝素製劑。在1933年之前，肝素相當的昂貴且具有高毒性；在康諾特醫學研究實驗室（當時屬於多倫多大學）以四年的時間（1933-1936）將生產肝素的製程優化後，肝素終於可以使用於生理食鹽水中。肝素的第一個人體試驗發生在1935年五月，到了1937年已經確定為安全、有效且容易取得的抗凝血劑了<ref>{{cite web|last=Rutty |first=CJ |title=Miracle Blood Lubricant: Connaught and the Story of Heparin, 1928–1937 |publisher=Health Heritage Research Services |url=http://www.healthheritageresearch.com/Heparin-Conntact9608.html |accessdate=2007-05-21 |deadurl=yes |archiveurl=https://web.archive.org/web/20070823120920/http://www.healthheritageresearch.com/Heparin-Conntact9608.html |archivedate=August 23, 2007 }}</ref>。

==肝素的其他功能==<!--bit of a dustbin title, and can't we organise this better than a random list?-->
*作為抗凝血劑，肝素不像[[乙二胺四乙酸|乙二胺四乙酸]]（EDTA）會與大部分的離子結合，造成干擾；因此臨床採血管與[[毛細管|毛細管]]常使用[[鋰|鋰]]肝素作為抗凝血劑。加入鋰肝素作為抗凝血劑的採血管與毛細管以綠色貼紙與管蓋標示。如需要測定鋰離子濃度時，可以使用含有[[钠|鈉]]肝素的採血管（以藍色蓋子標示）。雖然肝素與EDTA相比，對血液離子濃度的測定干擾極小，但高量的肝素可能會影響到鈣離子濃度<ref>{{cite journal | author= Higgins, C. | title= The use of heparin in preparing samples for blood-gas analysis | journal= Medical Laboratory Observer | date= October 2007 | url= http://www.mlo-online.com/articles/200710/1007cover_story.pdf | format= PDF | access-date= 2017-05-15 | archive-url= https://web.archive.org/web/20160910124849/http://www.mlo-online.com/articles/200710/1007cover_story.pdf | archive-date= 2016-09-10 | dead-url= yes }}</ref>；也曾發現肝素會干擾免疫測定。
*使用體外循環機時會配合使用以肝素塗層的血液充氧器，藉由提供接近血管內皮細胞的環境來提升整體的生物相容性與病人的生理平衡。
*[[RNA聚合酶|核糖核酸聚合酶]]的去氧核糖核酸結合位址可與肝素結合，造成它無法與基因上的啟動子結合；這個特性在許多分子生物的試驗上非常有用。
*雖然使用肝素作為抗凝血劑所採取的血，可以由其中的白血球取得足夠的DNA來進行[[聚合酶链反应|聚合酶鏈反應]]；但研究者也發現即使是微量的肝素（每50 μL 0.002單位），還是會干擾聚合酶鏈反應的進行<ref>{{cite journal | author=Yokota M, Tatsumi N, Nathalang O, Yamada T, Tsuda I. | title = Effects of Heparin on Polymerase Chain Reaction for Blood White Cells | journal = J. Clin. Lab. Anal. | year=1999 | volume=13 | pages=133–140 | pmid = 10323479 | doi=10.1002/(SICI)1098-2825(1999)13:3<133::AID-JCLA8>3.0.CO;2-0 | issue=3| last2 = Tatsumi | last3 = Nathalang | last4 = Yamada | last5 = Tsuda }}</ref>。

==關於肝素的社會與文化議題==

===污染召回===
相比於完全由化學合成的治療藥劑，由動物來源萃取純化的肝素潛在的不純物當然多得多了：包括病毒、細菌的內毒素、普利昂蛋白、脂肪、蛋白質與去氧核糖核酸都有可能出現在其中；而純化過程中所使用的溶劑、重金屬以及離子等也不無可能成為污染物。雖然這樣說，但過去已經建立了許多方法來將不純物/污染物含量盡可能的降低，這些方法也都詳列於藥典中。目前分析肝素的污染物最大的困難，首推如何鑑定如硫化皮膚素（DS，一名硫化軟骨素B）這類結構與肝素類似的污染物。硫化皮膚素由N-乙酰-半乳糖胺（GalN）與醣醛酸以1→3連結所組成的雙糖形成，雙糖之間以1→4形式相連。醣醛酸部分可能為葡萄醣醛酸、艾杜醣醛酸、2-''O''-硫-α-{{small|L}}-艾杜糖醛酸，六碳糖的部分除了乙酰半乳糖胺以外，也有可能在四號碳及/或六號碳的位置硫化（Gal- NAc4S, GalNAc6S, 或 GalNAc4S6S）。艾杜糖醛酸的存在使硫化皮膚素與硫化軟骨素A與C不同，但卻使它與肝素較為相似，但比肝素的陰電密度要低。通常在肝素中大約有1-7%的硫化皮膚素，但它們不具有肝素的生物活性<ref name="pmid20814668">{{cite journal | author = Szabolcs Beni, John F. K. Limtiaco, Cynthia K. Larive| title = Analysis and characterization of heparin impurities| journal = Analytical and Bioanalytical Chemistry   | volume = 399 | issue = 2 | pages = 527–539  |date=September 2011 | pmid =20814668 | doi = 10.1007/s00216-010-4121-x | pmc = 3015169  | last2 = Limtiaco| last3 = Larive}}</ref>。 

2007年12月，[[美国食品药品监督管理局|美國食品藥品監督管理局]]發現有一批肝素製劑遭到粘質沙雷氏菌污染而全面回收。粘質沙雷氏菌感染嚴重可致死<ref>[http://www.fda.gov/oc/po/firmrecalls/am2pat12_07.html ''AM2 PAT, Inc. Issues Nationwide Recall of Pre-Filled Heparin Lock Flush Solution USP (5 mL in 12 mL Syringes)''] {{Wayback|url=http://www.fda.gov/oc/po/firmrecalls/am2pat12_07.html |date=20071223165114 }}, Am2pat, Inc. Press release, December 20, 2007{{Failed verification|date=2010年3月}}</ref>。

{{Main article|2008年中國肝素摻假}}
2008年三月，美國食品藥物監督管理局發現由中國進口的一批肝素遭到[[硫酸軟骨素蛋白聚醣|硫化軟骨素]]污染，並造成81人死亡，宣布全面回收<ref>CBS News, [http://www.cbsnews.com/stories/2008/03/01/eveningnews/main3896578.shtml Blood-thinning drug under suspicion] {{Wayback|url=http://www.cbsnews.com/stories/2008/03/01/eveningnews/main3896578.shtml |date=20130517090538 }}</ref><ref>[http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM112597 FDA informational page] {{Wayback|url=http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM112597 |date=20180425015342 }} with information and links about FDA investigation.</ref>。這些硫化軟骨素是一般硫化軟骨素的「過度硫化」型態，原本適用於[[关节炎|關節炎]]的治療，但卻被加到肝素裡面企圖矇混過活性測試<ref>{{cite web|url=http://www.fda.gov/downloads/NewsEvents/Newsroom/MediaTranscripts/UCM169342.pdf|title=FDA Media Briefing on Heparin|publisher=[[美国食品药品监督管理局|U.S. Food and Drug Administration]]|first=Julie|last=Zawisza|date=29 March 2008|accessdate=2008-04-23|format=PDF|archive-date=2010-03-06|archive-url=https://web.archive.org/web/20100306183003/http://www.fda.gov/downloads/NewsEvents/Newsroom/MediaTranscripts/UCM169342.pdf|dead-url=no}}</ref>。

===2008年污染召回 ===

2008年三月，藥廠因為未知的污染宣布召回一批來自中國的肝素<ref>''New York Times'', March 6, 2008 Drug Tied to China Had Contaminant, F.D.A. Says'', retrieved 2008-03-07</ref><ref>''New York Times'', March 7, 2008 German Authorities Report Problems With Blood Thinner'', retrieved 2008-03-07</ref>。後來發現這些肝素遭到「過度硫化」的硫化軟骨素污染<ref>{{cite journal | last1= Blossom | first1 = DB | year = 2008 | title = Outbreak of adverse reactions associated with contaminated heparin | journal = N Engl J Med. | volume = 359 | issue = 25| pages = 2674–84 | doi = 10.1056/NEJMoa0806450 | pmid = 19052120 | last2 = Kallen | first2 = AJ | last3 = Patel | first3 = PR | last4 = Elward | first4 = A | last5 = Robinson | first5 = L | last6 = Gao | first6 = G | last7 = Langer | first7 = R | last8 = Perkins | first8 = KM | last9 = Jaeger | first9 = JL |displayauthors=8 | pmc=3810025}}</ref>，美國食品藥物監督管理局宣布至少有十九個人因此死亡，另外還有785人因為使用了這些污染的肝素，造成呼吸困難、噁心、嘔吐、大量流汗、血壓急速下降甚至休克等症狀。

===使用於謀殺===
2006年，任職於[[捷克|捷克]]的一名護理師[[佩特·澤倫卡|澤倫卡]]以注射過量肝素的方式謀殺十七名病人，造成七人死亡<ref>[http://www.radio.cz/en/article/85964 Nurse committed murders to "test" doctors] {{Wayback|url=http://www.radio.cz/en/article/85964 |date=20100410140133 }}, Radio Praha, May 12, 2006</ref>。

===過量問題===
一名任職於雪松-西奈醫療中心的護理師在2007年錯誤地注射了成人劑量（約為嬰兒劑量的1000倍）的肝素到[[丹尼斯·奎德|丹尼斯‧奎德]]12天大的雙胞胎體內<ref>Ornstein, Charles; Gorman, Anna. (November 21, 2007) [[洛杉磯時報|Los Angeles Times]] ''[http://www.cnn.com/2007/SHOWBIZ/Movies/11/21/quaid.newborns.ap/index.html Report: Dennis Quaid's twins get accidental overdose.]'' {{webarchive |url=https://web.archive.org/web/20080307193136/http://www.cnn.com/2007/SHOWBIZ/Movies/11/21/quaid.newborns.ap/index.html |date=March 7, 2008 }}</ref>。因為藥廠（百特國際）提供的成人與嬰兒包裝的肝素外表相似，奎德家族雖然與醫院以75萬美金和解<ref>[http://www.sfgate.com/cgi-bin/blogs/dailydish/detail?blogid=7&entry_id=33678 Quaid Awarded $750,000 Over Hospital Negligence] {{Wayback|url=http://www.sfgate.com/cgi-bin/blogs/dailydish/detail?blogid=7&entry_id=33678 |date=20090415140001 }}, SFGate.com, December 16, 2008</ref>，但仍決定對百特國際提告<ref>[http://www.usatoday.com/life/people/2007-12-04-quaid-lawsuit_N.htm Dennis Quaid and wife sue drug maker] {{Wayback|url=http://www.usatoday.com/life/people/2007-12-04-quaid-lawsuit_N.htm |date=20100628031940 }}, USA Today, December 4, 2007</ref><ref>[http://www.latimes.com/features/health/la-me-quaid5dec05,1,1883436.story Dennis Quaid files suit over drug mishap] {{Wayback|url=http://www.latimes.com/features/health/la-me-quaid5dec05,1,1883436.story |date=20120219174219 }}, Los Angeles Times, December 5, 2007</ref>。在奎德家族的不幸事件發生之前，已經有六個在印第安納波利斯的衛理公會醫院的嬰兒也被錯誤地注射了成人劑量，並造成三人死亡<ref>[http://www.wthr.com/Global/story.asp?s=5418800 WTHR story] {{webarchive|url=https://web.archive.org/web/20110629131727/http://www.wthr.com/Global/story.asp?s=5418800 |date=2011-06-29 }} about Methodist Hospital overdose</ref>。

2008年7月，在德州[[科珀斯克里斯蒂_(得克萨斯州)|聖體市]]的 Christus Spohn 醫院出生的雙胞胎，因為醫院藥局出錯被注射了過量的肝素而死<ref>[http://christusspohn.netreturns.biz/NewsReleases/Article_Detail.aspx?id=b8250e15-c437-48f3-8345-edc85a47565a Statement by Dr. Richard Davis, Chief Medical Officer, CHRISTUS Spohn Health System]{{dead link|date=2018年1月 |bot=InternetArchiveBot |fix-attempted=yes }}, July 10, 2008</ref>，目前該案件仍在調查<ref>[http://www.dallasnews.com/sharedcontent/dws/news/texassouthwest/stories/DN-bloodthinner_11tex.ART.State.Edition1.4d4aa44.html At a Glance Heparin Overdose at Hospital] {{Wayback|url=http://www.dallasnews.com/sharedcontent/dws/news/texassouthwest/stories/DN-bloodthinner_11tex.ART.State.Edition1.4d4aa44.html |date=20081025104636 }}, Dallas Morning News, July 11. 2008</ref><ref>"[http://abcnews.go.com/GMA/Parenting/story?id=5346509&page=1 Officials Investigate Infants' Heparin OD at Texas Hospital] {{Wayback|url=http://abcnews.go.com/GMA/Parenting/story?id=5346509&page=1 |date=20170911024203 }}." ''[[ABC新聞|ABC News]].'' July 11, 2008. Retrieved on July 24, 2008.</ref>。2010年3月，來自德州的一名兩歲的器官移植病人在內布拉斯加大學醫學中心因被注射了致死劑量的肝素而死，該案目前也仍在調查<ref>"[http://www.ketv.com/news/23020944/detail.html Heparin Overdose Kills Toddler At Hospital, Staff Investigated] {{webarchive|url=https://web.archive.org/web/20120320093130/http://www.ketv.com/news/23020944/detail.html |date=2012-03-20 }}." "KETV Omaha." March 31, 2010.</ref>。 

===肝素的產製===
製藥級的肝素是從[[屠宰|屠宰]]動物的[[黏膜|黏膜]]（如[[家豬|豬]]腸或[[牛|牛]]肺）純化而來<ref>{{cite journal | author = Linhardt RJ, Gunay NS. | title = Production and Chemical Processing of Low Molecular Weight Heparins | journal = Sem. Thromb. Hem. | year=1999 | volume=3 | pages=5–16 | pmid = 10549711 | last2 = Gunay }}</ref>。全合成肝素的技術正持續地研發<ref>{{cite web|last=Bhattacharya|first=Ananyo|title=Flask synthesis promises untainted heparin|url=http://www.rsc.org/chemistryworld/News/2008/August/19080803.asp|work=Chemistry World|publisher=Royal Society of Chemistry|accessdate=6 February 2011|date=August 2008|archive-date=2012-10-21|archive-url=https://web.archive.org/web/20121021055549/http://www.rsc.org/chemistryworld/News/2008/August/19080803.asp|dead-url=no}}</ref>，以化學酶法工藝從雙糖合成低分子量肝素的方法已在2011年被研發出來<ref>{{Cite journal | doi = 10.1126/science.1207478| pmid = 22034431| title = Chemoenzymatic Synthesis of Homogeneous Ultralow Molecular Weight Heparins| journal = Science| volume = 334| issue = 6055| pages = 498–501| year = 2011| last1 = Xu | first1 = Y.| last2 = Masuko | first2 = S.| last3 = Takieddin | first3 = M.| last4 = Xu | first4 = H.| last5 = Liu | first5 = R.| last6 = Jing | first6 = J.| last7 = Mousa | first7 = S. A.| last8 = Linhardt | first8 = R. J.| last9 = Liu | first9 = J.
| pmc = 3425363}}</ref>。

===研究===
肝素除了作為抗凝血劑之外，將類似肝素的結構開發為[[药物|藥劑]]的潛力也不容忽視。肝素潛在的用途如下表所示<ref name=lever>{{cite journal |author1=Lever R. |author2=Page C.P. | title = Novel drug opportunities for heparin | journal= Nature Reviews Drug Discovery  | year=2002 | volume=1 | issue=2 | pages=140–148 | pmid = 12120095 | doi=10.1038/nrd724}}</ref><ref name=coombe>{{cite journal |author1=Coombe D.R. |author2=Kett W.C. | title = Heparan sulfate-protein interactions: therapeutic potential through structure-function insights | journal= Cell. Mol. Life Sci. | year=2005 | volume=62 | issue=4 | pages=410–424 | pmid = 15719168 | doi = 10.1007/s00018-004-4293-7}}</ref>：

{| class="wikitable" style="text-align:left"
|- valign="top"
| |'''對肝素敏感的疾病'''||'''目前肝素在實驗模型上的效果''' || '''臨床狀態'''
|- valign="top"
|| [[艾滋病|艾滋病]] || 降低培養的T淋巴球對第一型與第二型人類免疫缺乏病毒的吸收<ref>{{cite journal |author=Baba M, Pauwels R, Balzarini J, Arnout J, Desmyter J, De Clercq E |title=Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro |journal=PNAS |volume=85 |issue=16 |pages=6132–6 |year=1988 |pmid=2457906 |bibcode=1988PNAS...85.6132B |last2=Pauwels |last3=Balzarini |last4=Arnout |last5=Desmyter |last6=De Clercq |doi=10.1073/pnas.85.16.6132 |pmc=281919}}</ref>。 || -
|- valign="top"
||  [[急性呼吸窘迫症候群|急性呼吸窘迫症候群]] || 在[[动物模型|動物模型]]中，肝素可以降低呼吸道中細胞的活化與聚集、中和對細胞有毒的細胞產物、提升肺部功能。  || 對照[[臨床試驗|臨床試驗]]
|- valign="top"
||  過敏性腦脊髓炎 || 在動物模型中有療效。|| -
|- valign="top"
||  [[過敏性鼻炎|過敏性鼻炎]] || 雖然對成人呼吸窘迫症候群有療效，但在鼻炎中沒有被測試過。  || 對照臨床試驗
|- valign="top"
||  [[关节炎|关节炎]] || 可抑制細胞聚集、[[膠原蛋白|膠原蛋白]]受損與[[血管新生|血管增生]]。  || [[軼事證據|軼事證據]]
|- valign="top"
||  [[哮喘|哮喘]] || 如成人呼吸窘迫症候群的發現，在實驗動物中發現肝素對提升肺部功能有幫助。 || 對照臨床試驗
|- valign="top"
||  [[癌症|癌症]] || 在動物模型中，肝素可以抑制[[癌|癌]]的生長、[[遠端轉移|遠端轉移]]、[[血管新生|血管新生]]，從而提升存活時間。  || 一些軼事證據
|- valign="top"
||  [[超敏反應|第四型過敏反應]] || 在動物模型中有療效。  || -
|- valign="top"
||  [[炎症性肠病|炎症性肠病]] || 抑制發炎細胞運輸。  || 對照臨床試驗
|- valign="top"
||  [[間質性膀胱炎|間質性膀胱炎]] || 在人類的實驗中可以抑制間質性膀胱炎。 || 已在臨床使用
|- valign="top"
|| [[移植排斥|移植排斥]] || 在動物模型中，肝素可以延長異體移植器官壽命。 || -
|}
- 表示沒有資訊可參考。

由於研究發現肝素對許多疾病都可能會有療效，目前已有一些在結構上與肝素類似的新藥物正在開發中<ref name=lever/>，如下表所示：

{| class="wikitable" style="text-align:left"
|- valign="top"
| |'''藥物分子'''||'''新藥與肝素比較''' || '''生物活性'''
|- valign="top"
||  肝素四糖 || 非抗凝血劑、不具抗原性、可口服  || 抗過敏劑
|- valign="top"
||  戊聚醣多硫酸鹽 || 由植物分子衍生而來、微小抗凝血活性、抗發炎、可口服|| 抗發炎、抗黏著、抗遠端轉移
|- valign="top"
||  磷酸戊糖甘露糖硫酸鹽 || 抑制肝素酶活性的有效[[抑制剂|抑制劑]]  || 抗遠端轉移、抗血管新生、抗發炎
|- valign="top"
||  化學選擇性O-去硫肝素 || 不具抗凝血活性 || 抗發炎、抗過敏、抗黏著
|}

==參考文獻==
{{Reflist|30em}}

== 延伸閱讀 ==
*{{cite journal |author=Marcum JA |title=The origin of the dispute over the discovery of heparin |journal=Journal of the History of Medicine and Allied Sciences |volume=55 |issue=1 |pages=37–66 |date=January 2000 |pmid=10734720 |doi=10.1093/jhmas/55.1.37 |url=http://jhmas.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=10734720 |access-date=2016-06-07 |archive-date=2020-05-30 |archive-url=https://web.archive.org/web/20200530141350/https://academic.oup.com/jhmas |dead-url=yes }}
*{{Cite journal|url = |title = Pharmacology of Heparin and Related Drugs|date = January 2016|journal = {{tsl|en|Pharmacol. Rev.||Pharmacological Reviews}}|doi = 10.1124/pr.115.011247|pmid = |vauthors = Mulloy B, Hogwood J, Gray E, Lever R, Page CP |volume=68 |pages=76–141}}<!--|access-date = 31 December 2015-->

==外部連結==
{{Portal|藥理學}}

{{commons category|Heparin}}
*[https://web.archive.org/web/20070823120920/http://www.healthheritageresearch.com/Heparin-Conntact9608.html History of heparin]

{{Antithrombotics}}
{{Vasoprotectives}}
{{Glycosaminoglycans}}

{{Authority control}}

{{tsl|en|Category:Chemical substances for emergency medicine||Category:Chemical substances for emergency medicine}}
[[Category:糖胺聚糖|Category:糖胺聚糖]]
[[Category:肝素|Category:肝素]]
[[Category:世界卫生组织基本药物|Category:世界卫生组织基本药物]]